FDA Advises Eurand (EURX) That It Has Extended the Review Period for ZENPEP(TM) Therapy
Tweet Send to a Friend
Eurand N.V. (NASDAQ: EURX) announced that the U.S. FDA has advised the Company that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
